HUN Stock Analysis: Huntsman | NYSE
Chemicals | NYSE, USA | Market Cap: 1.675m USD | 12M Return: 31.3% | US4470111075 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 25.8M
Qual. Beats: 0
Rev. Trend: -37.7%
Qual. Beats: 3
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Huntsman Corporation (HUN) is a U.S.-based diversified chemical manufacturer founded in 1970 and headquartered in The Woodlands, Texas. The company produces organic chemical products through three operating segments: Polyurethanes, Performance Products, and Advanced Materials. Its Polyurethanes segment produces MDI, polyols, thermoplastic polyurethane, and co-products such as aniline and benzene. The Performance Products segment focuses on amines and specialty catalysts, while the Advanced Materials segment supplies epoxy, acrylic, and polyurethane-based polymer formulations, thermoset resins, and carbon nanomaterials.
Huntsman sells its products globally through a network of distributors and agents, and provides pre- and post-sales technical service support to customers. Its products serve a broad range of end markets, including automotive, aerospace, construction, electronics, insulation, packaging, oil and gas (including LNG transport), coatings, power generation, footwear, appliances, and medical applications. As a member of the GICS Materials sector and the Diversified Chemicals sub-industry, Huntsman functions as an upstream chemical supplier, with its outputs feeding into numerous industrial value chains rather than selling directly to end consumers.
- MDI oversupply pressures polyurethane segment margins
- European industrial weakness dampens specialty chemicals demand
- Aerospace recovery accelerates advanced materials epoxy resin growth
| Net Income: -93.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA -3.94 > 1.0 |
| NWC/Revenue: 15.74% < 20% (prev 10.05%; Δ 5.69% < -1%) |
| CFO/TA 0.01 > 3% & CFO 78.0m > Net Income -93.0m |
| Net Debt (2.10b) to EBITDA (308.0m): 6.81 < 3 |
| Current Ratio: 1.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (173.0m) vs 12m ago 0.23% < -2% |
| Gross Margin: 13.47% > 18% (prev 13.41%; Δ 0.06% > 0.5%) |
| Asset Turnover: 86.78% > 50% (prev 81.62%; Δ 5.16% > 0%) |
| Interest Coverage Ratio: 0.24 > 6 (EBIT TTM 21.0m / Interest Expense TTM 86.0m) |
| A: 0.14 (Total Current Assets 2.13b - Total Current Liabilities 1.17b) / Total Assets 7.10b |
| B: 0.25 (Retained Earnings 1.81b / Total Assets 7.10b) |
| C: 0.00 (EBIT TTM 21.0m / Avg Total Assets 7.09b) |
| D: 27.88 (Book Value of Equity 6.86b / Total Liabilities 246.0m) |
| Altman-Z'' = 31.02 = AAA |
| DSRI: 1.06 (Receivables 870.0m/768.0m, Revenue 6.16b/5.78b) |
| GMI: 1.00 (GM 13.41% / 13.47%) |
| AQI: 1.26 (AQ_t 0.37 / AQ_t-1 0.29) |
| SGI: 1.06 (Revenue 6.16b / 5.78b) |
| TATA: -0.02 (NI -93.0m - CFO 78.0m) / TA 7.10b) |
| Beneish M = -2.78 (Cap -4..+1) = A |
As of November 08, 2026, the stock is trading at USD 9.45 with a total of 2,892,899 shares traded. Over the past week, the price has changed by -1.97%, over one month by +7.75%, over three months by -5.92% and over the past year by +31.26%.
Current recommended Stop Loss: 8.60 (which is 9% or 2.1 ATR below the current price).
Huntsman has received a consensus analysts rating of 3.07. Therefore, it is recommended to hold HUN.
- StrongBuy: 2
- Buy: 0
- Hold: 11
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 10.3 | 8.9% |
P/E Forward = 58.4795
P/S = 0.284
P/B = 0.6482
P/EG = 2.2202
Revenue TTM = 6.16b USD
EBIT TTM = 21.0m USD
EBITDA TTM = 308.0m USD
Long Term Debt = 1.66b USD (from longTermDebt, last fiscal year)
Short Term Debt = 303.0m USD (from shortTermDebt, last quarter)
Debt = 2.46b USD (from shortLongTermDebtTotal, last quarter) + Leases 414.0m
Net Debt = 2.10b USD (calculated: Debt 2.46b - CCE 359.0m)
Enterprise Value = 3.77b USD (1.67b + Debt 2.46b - CCE 359.0m)
Interest Coverage Ratio = 0.24 (Ebit TTM 21.0m / Interest Expense TTM 86.0m)
EV/FCF = -47.16x (Enterprise Value 3.77b / FCF TTM -80.0m)
FCF Yield = -2.12% (FCF TTM -80.0m / Enterprise Value 3.77b)
FCF Margin = -1.30% (FCF TTM -80.0m / Revenue TTM 6.16b)
Net Margin = -1.51% (Net Income TTM -93.0m / Revenue TTM 6.16b)
Gross Margin = 13.47% ((Revenue TTM 6.16b - Cost of Revenue TTM 5.33b) / Revenue TTM)
Gross Margin QoQ = 13.80% (prev 14.73%)
Tobins Q-Ratio = 0.53 (Enterprise Value 3.77b / Total Assets 7.10b)
Interest Expense / Debt = 3.50% (Interest Expense 86.0m / Debt 2.46b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 16.6m (EBIT 21.0m * (1 - 21.00%))
Current Ratio = 1.83 (Total Current Assets 2.13b / Total Current Liabilities 1.17b)
Debt / Equity = 0.36 (Debt 2.46b / totalStockholderEquity, last quarter 6.86b)
Debt / EBITDA = 6.81 (Net Debt 2.10b / EBITDA 308.0m)
Debt / FCF = -26.23 (negative FCF - burning cash) (Net Debt 2.10b / FCF TTM -80.0m)
Total Stockholder Equity = 3.75b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.31% (Net Income -93.0m / Total Assets 7.10b)
RoE = -2.48% (Net Income TTM -93.0m / Total Stockholder Equity 3.75b)
RoCE = 0.39% (EBIT 21.0m / Capital Employed (Equity 3.75b + L.T.Debt 1.66b))
RoIC = 0.28% (NOPAT 16.6m / Invested Capital 5.93b)
WACC = 5.33% (E(1.67b)/V(4.13b) * Re(9.09%) + D(2.46b)/V(4.13b) * Rd(3.50%) * (1-Tc(0.21)))
Discount Rate = 9.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 72.85 | Cagr: 0.05%
[DCF] Fair Price = unknown (Cash Flow -80.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.22 | # QB: 0
Revenue Correlation: -37.70 | Revenue CAGR: -1.06% | SUE: 4.0 | # QB: 3
EPS current Quarter (2027-03-31): EPS=-0.06 | Chg30d=-26.05% | Revisions=-25% | Analysts=5
EPS current Year (2026-12-31): EPS=-0.25 | Chg30d=-5.75% | Revisions=-29% | GrowthEPS=+64.2% | GrowthRev=+10.2%
EPS next Year (2027-12-31): EPS=0.24 | Chg30d=+4.94% | Revisions=-40% | GrowthEPS=+194.3% | GrowthRev=+0.4%
[Analyst] Revisions Ratio: -50% (up=1, down=6)